ENTRY       D12066                      Drug
NAME        Spesolimab (USAN/INN);
            Spesolimab (genetical recombination) (JAN);
            Spesolimab-sbzo;
            Spevigo (TN)
PRODUCT     SPEVIGO (Boehringer Ingelheim Pharmaceuticals)
FORMULA     C6480H9988N1736O2012S46
EXACT_MASS  145787.9764
MOL_WEIGHT  145878.0547
SEQUENCE    (Heavy chain)
            QVQLVQSGAE VKKPGASVKV SCKASGYSFT SSWIHWVKQA PGQGLEWMGE INPGNVRTNY
            NENFRNKVTM TVDTSISTAY MELSRLRSDD TAVYYCTVVF YGEPYFPYWG QGTLVTVSSA
            STKGPSVFPL APSSKSTSGG TAALGCLVKD YFPEPVTVSW NSGALTSGVH TFPAVLQSSG
            LYSLSSVVTV PSSSLGTQTY ICNVNHKPSN TKVDKRVEPK SCDKTHTCPP CPAPEAAGGP
            SVFLFPPKPK DTLMISRTPE VTCVVVDVSH EDPEVKFNWY VDGVEVHNAK TKPREEQYNS
            TYRVVSVLTV LHQDWLNGKE YKCKVSNKAL PAPIEKTISK AKGQPREPQV YTLPPSREEM
            TKNQVSLTCL VKGFYPSDIA VEWESNGQPE NNYKTTPPVL DSDGSFFLYS KLTVDKSRWQ
            QGNVFSCSVM HEALHNHYTQ KSLSLSPGK
            (Light chain)
            QIVLTQSPGT LSLSPGERAT MTCTASSSVS SSYFHWYQQK PGQAPRLWIY RTSRLASGVP
            DRFSGSGSGT DFTLTISRLE PEDAATYYCH QFHRSPLTFG AGTKLEIKRT VAAPSVFIFP
            PSDEQLKSGT ASVVCLLNNF YPREAKVQWK VDNALQSGNS QESVTEQDSK DSTYSLSSTL
            TLSKADYEKH KVYACEVTHQ GLSSPVTKSF NRGEC
            (Disulfide bridge: H22-H96, H146-H202, H222-L215, H228-H'228, H231-H'231, H263-H323, H369-H427, H'22-H'96, H'146-H'202, H'222-L'215, H'263-H'323, H'369-H'427, L23-L89, L135-L195, L'23-L'89, L'135-L'195)
  TYPE      Peptide
CLASS       Immunological agent
             DG02019  Interleukin inhibitor
REMARK      Therapeutic category: 3999
            ATC code: L04AC22
            Product: D12066<JP/US>
EFFICACY    Antipsoriatic, Anti-IL-36 receptor antagonist
  DISEASE   Generalized pustular psoriasis [DS:H01663]
  TYPE      Monoclonal antibody
COMMENT     Treatment of immune and inflammatory disorders
TARGET      IL1RL2 (IL-36R) [HSA:8808] [KO:K05172]
  PATHWAY   hsa04060(8808)  Cytokine-cytokine receptor interaction
BRITE       Anatomical Therapeutic Chemical (ATC) classification [BR:br08303]
             L ANTINEOPLASTIC AND IMMUNOMODULATING AGENTS
              L04 IMMUNOSUPPRESSANTS
               L04A IMMUNOSUPPRESSANTS
                L04AC Interleukin inhibitors
                 L04AC22 Spesolimab
                  D12066  Spesolimab (USAN/INN) &lt;JP/US&gt;
            USP drug classification [BR:br08302]
             Immunological Agents
              Immunological Agents, Other
               Interleukin Blockers
                Spesolimab
                 D12066  Spesolimab (USAN/INN)
            Therapeutic category of drugs in Japan [BR:br08301]
             3  Agents affecting metabolism
              39  Other agents affecting metabolism
               399  Miscellaneous
                3999  Others
                 D12066  Spesolimab (USAN/INN); Spesolimab (genetical recombination) (JAN)
            Drug groups [BR:br08330]
             Immunological agent
              DG02019  Interleukin inhibitor
               D12066  Spesolimab
            Drug classes [BR:br08332]
             Immunological agent
              DG02019  Interleukin inhibitor
               D12066  Spesolimab
            Target-based classification of drugs [BR:br08310]
             Cytokines and receptors
              Cytokine receptors
               Interleukin receptors
                IL1RL2 (IL-36R)
                 D12066  Spesolimab (USAN/INN) &lt;JP/US&gt;
            New drug approvals in the USA [br08319.html]
             New molecular entities and new therapeutic biological products
              D12066
            New drug approvals in Japan [br08318.html]
             Drugs with new active ingredients
              D12066
            New drug approvals in the USA, Europe and Japan [br08328.html]
             Approval dates by FDA, EMA and PMDA
              D12066
DBLINKS     CAS: 2097104-58-8
///
